Pharmaceuticals Biotechnology and Life Sciences
featured
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
» Read More
More
-
In a study that could change the way hip fractures are treated, doctors have discovered that giving the Novartis osteoporosis drug Reclast can prevent later fractures and helps patients live longer.
-
Drug developer Eli Lilly said Friday the Food and Drug Administration approved its osteoporosis drug Evista for use in reducing the risk of invasive breast cancer.
-
Cephalon has warned doctors about at least three deaths linked to its cancer pain drug Fentora, U.S. health regulators said on Thursday.
-
Bayer's heart surgery drug, Trasylol, linked in some studies with an increased risk of death, should remain on the market, advisors to the U.S. Food and Drug Administration said onWednesday.
-
As far as he's concerned, there are plenty of reasons to own this medical diagnostics company.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Every stock in a portfolio has a role to play the same way players do on the field. Here are Cramer's picks for wide-receiver.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
French biopharmaceutical company Flamel Technologies said Wednesday it signed a development and license agreement with the pharmaceuticals unit of drug developer Wyeth.
-
A panel of advisers to U.S. health regulators voted on Tuesday to reject new restrictions on anemia drugs, a win for drugmakers Amgen and Johnson & Johnson .
-
The cancer drug Erbitux unexpectedly extended survival in a trial of patients with advanced lung cancer, sending shares of its maker, ImClone Systems, soaring as much as 24 percent.
-
Is the Senate coming to the rescue of patients, investors or both? That's the question being raised after the passage of a non-binding resolution telling Medicare to "immediately reconsider" its new policy to cut anemia drug use and reimbursement. Analysts are stunned by the move.
-
Highly publicized government warnings that antidepressants could cause suicidal thoughts in adolescents may have scared off parents and doctors alike, meaning fewer depressed children are being diagnosed, U.S. psychiatrists say.
-
CNBC talks to the the experts about what investors should do in this market.
-
Biovail said Tuesday it received Canadian approval for its once-daily, extended-release formulation of its tramadol pain treatment, giving the stock a much-needed dose of positive news.
-
Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.
-
A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.
-
Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.
-
Pfizer on Wednesday said it named Frank A. D'Amelio, a senior executive of Alcatel-Lucent, as chief financial officer of the drugmaker.
-
Shares of Dendreon rose Monday after the company said its breast cancer drug was effective in an early stage clinical trial.
-
On Amgen's conference call the other day regarding the biotech company's cutbacks, officials repeatedly stated that they think the federal government's new, restrictive guidelines for use and payment of Amgen's bread-and-butter anemia drugs will hurt patients and specifically, result in the need for more risky, old-fashioned blood transfusions to treat the condition.
-
Amgen shares plunged to a 52-week low on Thursday in the wake of the biotechnology firm’s announcement that it will lay off more than 2,000 and as many as 2,600 employees--or 12 percent to 14 percent of its labor force.